About Kenneth Wild
Form D filings for Avalor Therapeutics in 2023 list Kenneth Wild as director.
Kenneth Wild first appears on SEC filings in 2023.
Experience
This experience comes from SEC filings. The years are when the filings name Kenneth Wild in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Kenneth Wild works with at each company, as listed on that company's latest Form D.
Avalor Therapeutics, Inc. · Form D, Dec 5, 2023
WZ
William Martinez Zegarra
President and director
AF
Anthony Ford
Director